BCEIE › News › EPIGRAL

Credit rating

CRISIL assigns Epigral at CRISIL AA

Epigral (EPIGRAL) said CRISIL has assigned its credit rating at CRISIL AA, covering facilities or instruments of about ₹1,050 crore. The company is valued at about ₹3,914 crore.

BCEIE News Desk · Published 29 Oct 2026, 11:19 pm IST · Filing received 29 Oct 2026, 11:03 pm IST

What happened

Epigral (EPIGRAL) told the exchanges on 29 October 2026 at 11:03 PM that CRISIL has assigned its credit rating at CRISIL AA, covering facilities or instruments of about ₹1,050 crore.

Company snapshot

Epigral is a small-cap company, with a market value of about ₹3,914 crore.

The stock last traded at ₹907.3, against a 52-week range of ₹807–₹1,729.9 (47.5% below the high).

Before this filing the shares had moved −14.9% over the month and −22.9% over three months. Average daily turnover over the last 20 sessions was about ₹3.97 crore.

Promoters held 68.83% at the end of Q1 FY27. Foreign institutions owned 1.03% and domestic institutions 5.56%.

Quarterly results (consolidated, ₹ crore)
QuarterRevenueNet profitEPS (₹)
Q1 FY26607160.737.25
Q2 FY2658751.211.87
Q3 FY2659739.19.07
Q4 FY267368118.76
Q1 FY2770599.723.12

What history shows

This is not the company's first credit rating disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.

After those filings, the stock gained 2.4% on average the next trading day and was up 1.4% on average after five days (2 filings with price data).

Market-wide, 1,362 credit rating filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 46% rising.

Past reactions describe what happened before; they are not a forecast.

Earlier filings of this kind
DateFilingNext day5 days
14 Jul 2026Credit rating+1.9%+8.7%
3 Jun 2026Credit Rating+3.0%−5.9%

What to watch

  • Whether other agencies take a similar view on the company's credit.
  • 2 November 2026: Board meeting — Financial Results.

In the news

Recent coverage elsewhere (links open the original publisher):

Source

Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.

More on Epigral Limited